pBabe-c-myc-zeo Citations (9)

Originally described in: Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis.
Dai C, Whitesell L, Rogers AB, Lindquist S Cell. 2007 Sep 21. 130(6):1005-18. PubMed Journal

---

Articles Citing pBabe-c-myc-zeo

Articles
DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets. Hanaford AR, Archer TC, Price A, Kahlert UD, Maciaczyk J, Nikkhah G, Kim JW, Ehrenberger T, Clemons PA, Dancik V, Seashore-Ludlow B, Viswanathan V, Stewart ML, Rees MG, Shamji A, Schreiber S, Fraenkel E, Pomeroy SL, Mesirov JP, Tamayo P, Eberhart CG, Raabe EH. Clin Cancer Res. 2016 Mar 24. PubMed
Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine. Wang SZ, Poore B, Alt J, Price A, Allen SJ, Hanaford AR, Kaur H, Orr BA, Slusher BS, Eberhart CG, Raabe EH, Rubens JA. Clin Cancer Res. 2019 Oct 1;25(19):5925-5936. doi: 10.1158/1078-0432.CCR-19-0189. Epub 2019 Jul 12. PubMed
Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma. Hanaford AR, Alt J, Rais R, Wang SZ, Kaur H, Thorek DLJ, Eberhart CG, Slusher BS, Martin AM, Raabe EH. Transl Oncol. 2019 Oct;12(10):1314-1322. doi: 10.1016/j.tranon.2019.05.013. Epub 2019 Jul 21. PubMed
Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway. Wang M, Law ME, Davis BJ, Yaaghubi E, Ghilardi AF, Ferreira RB, Chiang CW, Guryanova OA, Kopinke D, Heldermon CD, Castellano RK, Law BK. Cell Death Discov. 2019 Dec 10;5:153. doi: 10.1038/s41420-019-0228-9. eCollection 2019. PubMed
An Excitable Ras/PI3K/ERK Signaling Network Controls Migration and Oncogenic Transformation in Epithelial Cells. Zhan H, Bhattacharya S, Cai H, Iglesias PA, Huang CH, Devreotes PN. Dev Cell. 2020 Sep 14;54(5):608-623.e5. doi: 10.1016/j.devcel.2020.08.001. Epub 2020 Sep 1. PubMed
Counterintuitive production of tumor-suppressive secretomes from Oct4- and c-Myc-overexpressing tumor cells and MSCs. Li K, Sun X, Zha R, Liu S, Feng Y, Sano T, Aryal UK, Sudo A, Li BY, Yokota H. Theranostics. 2022 Mar 28;12(7):3084-3103. doi: 10.7150/thno.70549. eCollection 2022. PubMed
Proteomes from AMPK-inhibited peripheral blood mononuclear cells suppress the progression of breast cancer and bone metastasis. Li K, Sun X, Minami K, Tamari K, Ogawa K, Li H, Ma H, Zhou M, Na S, Li BY, Yokota H. Theranostics. 2023 Feb 5;13(4):1247-1263. doi: 10.7150/thno.80294. eCollection 2023. PubMed
The inhibition of pancreatic cancer progression by K-Ras-overexpressing mesenchymal stem cell-derived secretomes. Huo Q, Li K, Sun X, Zhuang A, Minami K, Tamari K, Ogawa K, Fishel ML, Li BY, Yokota H. Sci Rep. 2023 Sep 12;13(1):15036. doi: 10.1038/s41598-023-41835-6. PubMed
Cooperativity of c-MYC with Kruppel-Like Factor 6 Splice Variant 1 induces phenotypic plasticity and promotes prostate cancer progression and metastasis. Izadmehr S, Fernandez-Hernandez H, Wiredja D, Kirschenbaum A, Lee-Poturalski C, Tavassoli P, Yao S, Schlatzer D, Hoon D, Difeo A, Levine AC, Mosquera JM, Galsky MD, Cordon-Cardo C, Narla G. bioRxiv [Preprint]. 2024 Feb 1:2024.01.30.577982. doi: 10.1101/2024.01.30.577982. PubMed

If you have published an article using this material, please email us at to have your article added to this page.